This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Ophthalmic disease				
Glaucoma	MAP kinase kinase kinase 12 (MAP3K12; DLK)	Rodent studies suggest inhibiting DLK could have neuroprotective effects that help treat glaucoma. In a mouse model for optic nerve damage, deletion of <i>Dlk</i> in retinal ganglion cells decreased the loss of those cells by 75% compared with no deletion. In a rat model for intraocular pressure-induced glaucoma, pretreatment with tozasertib, an inhibitor of multiple kinases including DLK, prevented disease progression. Next steps could include developing more selective DLK inhibitors. Tozasertib is a research reagent.	Patent and licensing status unavailable	Welsbie, D.S. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 19, 2013; doi:10.1073/pnas.1211284110 Contact: Donald J. Zack, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: dzack@jhmi.edu
SciBX 6(9); doi:10.1038/scibx.2013.223 Published online March 7, 2013				